Ramosetron for the management of chemotherapy-induced gastrointestinal events in patients with hematological malignancies.
The objective of this study was to evaluate the efficacy and safety of ramosetron hydrochloride for the management of nausea and vomiting induced by chemotherapy in patients with hematological malignancies. A total of 30 patients with hematological malignancies were included in the ramosetron group. Ramosetron (0.3 mg i.v.) was administered 0.5 h before chemotherapy. The impact of ramosetron on anorexia, nausea and vomiting as well as other adverse effects were assessed. Meanwhile, another 39 patients received tropisetron (o.d. for 3 days). As compared to the tropisetron group, the response rate of the ramosetron group in controlling anorexia within 18-24 h after chemotherapy was higher (p < 0.05); within 18-24 h after chemotherapy, the complete response rate and effective rate in controlling nausea was higher (p < 0.05); within 12-18 h and 18-24 h after chemotherapy, the complete response rate and effective rate in controlling vomiting was higher (p < 0.05). The incidence of adverse effects was similar in both groups. We conclude that ramosetron belongs to a new generation of 5-HT3 receptor antagonists and that it is a safe, economic and effective antiemetic drug.
Zeng
X Y
XY
Department of Hematology, Rui-Jin Hospital, Shanghai Second Medical University, Shanghai, P.R. China.
Wang
A H
AH
Liu
Y F
YF
Chen
Y
Y
Shen
Y
Y
Shen
Z X
ZX
D000293:Adolescent; D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects* / Q000627:therapeutic use; D001066:Appetite / Q000187:drug effects; D001562:Benzimidazoles / Q000627:therapeutic use*; D003248:Constipation / Q000139:chemically induced; D004244:Dizziness / Q000139:chemically induced; D064420:Drug-Related Side Effects and Adverse Reactions; D005260:Female; D005483:Flushing / Q000139:chemically induced; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000188:drug therapy*; D006261:Headache / Q000139:chemically induced; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced / Q000517:prevention & control; D013894:Thirst / Q000187:drug effects; D016896:Treatment Outcome; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced / Q000517:prevention & control
D000932:Antiemetics; D001562:Benzimidazoles; D007211:Indoles; D000077526:Tropisetron; C071315:ramosetron